NUVB Nuvation Bio Inc

  1. Stocks
  2. Healthcare
  3. NYSE: NUVB

Price (delayed)

$5.71

Market cap

$2B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.43

Enterprise value

$2.16B

?
Relative Growth: Rel. Growth: 30
Relative Strength: Rel. Strength: 66
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 37
Highlights
Nuvation Bio's revenue has increased by 19% from the previous quarter
The gross profit has grown by 15% from the previous quarter
The net income has increased by 26% year-on-year but it has declined by 2.6% since the previous quarter
The company's quick ratio fell by 14% YoY but it rose by 13% QoQ
Nuvation Bio's debt has surged by 105% YoY and by 92% QoQ
NUVB's equity is down by 32% year-on-year and by 21% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.nuvationbio.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of NUVB

NUVB stock price

How has the Nuvation Bio stock price performed over time
Intraday
-6.39%
1 week
-1.21%
1 month
-17.6%
1 year
77.33%
YTD
-36.27%
QTD
0.53%

Financial performance

How have Nuvation Bio's revenue and profit performed over time
Revenue
$169.9M
Gross profit
$149.81M
Operating income
-$137.63M
Net income
-$149.83M
Gross margin
88.2%
Net margin
-88.2%
The operating margin has soared by 95% YoY and by 23% QoQ
Nuvation Bio's net margin has surged by 94% YoY and by 14% QoQ
The operating income rose by 39% year-on-year and by 8% since the previous quarter
The net income has increased by 26% year-on-year but it has declined by 2.6% since the previous quarter

Price vs fundamentals

How does NUVB's price correlate with its fundamentals

Growth

What is Nuvation Bio's growth rate over time

Valuation

What is Nuvation Bio stock price valuation
P/E
N/A
P/B
7.85
P/S
11.72
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.73
NUVB's EPS is up by 10% YoY but it is down by 2.4% QoQ
NUVB's equity is down by 32% year-on-year and by 21% since the previous quarter
The stock's price to book (P/B) is 27% more than its last 4 quarters average of 6.6
The price to sales (P/S) is 58% less than the last 4 quarters average of 29.5
Nuvation Bio's revenue has increased by 19% from the previous quarter

Efficiency

How efficient is Nuvation Bio business performance
NUVB's ROS has soared by 95% YoY and by 17% QoQ
The return on invested capital has surged by 56% year-on-year and by 12% since the previous quarter
NUVB's return on assets is up by 35% year-on-year
NUVB's ROE is down by 13% from the previous quarter and by 8% YoY

Dividends

What is NUVB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NUVB.

Financial health

How did Nuvation Bio financials performed over time
The company's total assets is 52% higher than its total liabilities
The total liabilities has soared by 79% YoY and by 69% QoQ
The company's total assets rose by 22% QoQ and by 15% YoY
Nuvation Bio's debt is 64% higher than its equity
The debt to equity has soared by 198% YoY and by 141% QoQ
Nuvation Bio's debt has surged by 105% YoY and by 92% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.